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Abstract
Increased awareness of von Willebrand Disease (VWD) has led to more frequent
diagnostic laboratory testing, which insurers often dictate be performed at a facility
with off-site laboratory processing, instead of a coagulation facility with onsite
processing. Off-site processing is more prone to preanalytical variables causing
falsely low levels of von Willebrand Factor (VWF) due to the additional transport
required. Our aim was to determine the percentage of discordance between off-site
and onsite specimen processing for VWD in this multicenter, retrospective study.
We enrolled females aged 12 to 50 years who had off-site specimen processing for
VWF assays, and repeat testing performed at a consulting institution with onsite
coagulation phlebotomy and processing. A total of 263 females from 17 institutions
were included in the analysis. There were 251 subjects with both off-site and onsite
VWF antigen (VWF:Ag) processing with 96 (38%) being low off-site and 56 (22%)
low onsite; 223 subjects had VWF ristocetin co-factor (VWF:RCo), 122 (55%) were
low off-site and 71 (32%) were low onsite. Similarly, 229 subjects had a Factor VIII
(FVIII) assay, and 67 (29%) were low off-site with less than half, 29 (13%) confirmed
low with onsite processing. Higher proportions of patients demonstrated low VWF:
Ag, VWF:RCo, and/or FVIII with off-site processing compared to onsite (McNemarʼs
test P-value <.0005, for all assays). These results emphasize the need to decrease
delays from sample procurement to processing for VWF assays. The VWF assays
should ideally be collected and processed at the same site under the guidance of a
hematologist.
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1 | INTRODUCTION
Von Willebrand Disease (VWD) is the most common inherited bleed-
ing disorder, estimated to affect up to 1% of the population.1,2 Muco-
cutaneous bleeding is the hallmark of VWD, and is typified by
epistaxis, bruising, gum bleeding, gastrointestinal bleeding, bleeding
with trauma or surgery, as well as heavy menstrual bleeding (HMB). In
post-menarchal females, HMB may be the only presenting symptom
of VWD,3 and up to one-quarter of women and adolescents with
HMB have VWD.4-6 Unfortunately, many females with VWD have a
delay in diagnosis on average of 16 years despite extensive bleed-
ing.3,7 To prevent the delays in diagnosis and subsequent complica-
tions, The American College of Obstetricians and Gynecologists
(ACOG) advised that all patients with HMB, including adolescents, be
screened initially by history. Screening should then be by laboratory
testing for an underlying disorder of hemostasis, such as VWD, which
has resulted in an increased evaluation by non-hematology
specialists.8,9
The laboratory diagnosis of VWD is based on three main assays, a
quantitative measure of von Willebrand Factor (VWF) in the plasma,
the activity of VWF and specifically its ability to bind platelets and the
activity of Factor VIII (FVIII).10 Multiple clinical variables, such as phys-
iologic increases in VWF due to stress, illness, and cyclical estrogen
levels in post-menarchal females, as well as physiologic decreases in
VWF due to blood type, make correctly diagnosing VWD challeng-
ing.3,11 Additionally, pre-analytical and laboratory variables such as
inter-assay variability, poor assay sensitivity, sample collection tech-
nique, transportation, and storage contribute to the complexity of
making an accurate diagnosis.12-15
Insurers often dictate VWF assays to be performed at a labora-
tory within network (with off-site specimen processing), which is
often not a hospital or academic based coagulation laboratory with
onsite specimen processing. Onsite coagulation processing laborato-
ries can collect and process samples in a timely manner. This is in con-
trast to a laboratory where sample collection and processing often
take place at different locations leading to inevitable delays. Such a
delay results in artificially low VWF or FVIII levels due to preanalytical
variables, outside the control of the laboratories analyzing the sam-
ples.15,16 Patients may then be mislabeled as having the laboratory
diagnosis of VWD, leading to inappropriate interventions or inade-
quate therapy with attendant risks, lack of evaluation for alternate
bleeding conditions and increased health care costs due to repetitive
testing, consultation and treatment.17,18
To determine the consequences of collecting samples for VWF
testing and sending them off-site for processing compared to onsite
processing, a multi-site study was conducted. This study, to our
knowledge is the first multi-institutional evaluation of VWF testing in
post-menarchal females to determine the percentage with discordant
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testing results when comparing off-site to onsite coagulation
processing.
2 | METHODS
2.1 | Study design
We present a retrospective study conducted at 17 institutions
throughout the United States from July 2013 to October 2017. All
participating institutions were part of The Foundation for Women and
Girls with Blood Disorders, Learning Action Network (FWGBD LAN).
This network was created to provide collaboration, education and
resources for clinicians who care for women and girls with bleeding
and other blood disorders. The study was approved by the institu-
tional review board or given an exemption status at each institution.
2.2 | Study objectives
Our primary objective was to determine the percentage of post-
menarchal female patients with discordant VWF testing results when
blood samples were drawn and processed at the same coagulation
laboratory, vs when phlebotomy and processing were performed at
different sites. Secondary objectives were to determine how often
the referring physician (a) performed partial vs complete testing for
VWD and (b) referred a patient to a hematologist for VWD and they
were diagnosed with an alternative bleeding disorder.
2.3 | Study population
Eligible subjects were females of reproductive age, from 12 to
50 years who were referred to a hematologist due to the concern for
a bleeding disorder. All eligible subjects had testing for VWD with off-
site processing, which included at minimum a VWF antigen (VWF:Ag)
and/or VWF activity/ristocetin co-factor (VWF:RCo) assay. Study
subjects were then required to have VWF testing repeated at a con-
sulting institution under hematology supervision, with onsite coagula-
tion test phlebotomy and processing. Subjects were excluded from
the study if their hematology consultation was for reasons other than
a suspected bleeding disorder, or if subjects were referred from
another center with onsite coagulation laboratory processing and
analysis.
2.4 | Study procedures
Participating institutions identified and consecutively enrolled eligible
subjects who had at least one visit with the consulting hematologist
between July 2013 and October 2017. The subjectsʼ medical records
were reviewed retrospectively, including any medical history and labo-
ratory work performed prior to the hematology consultation. Onsite
processing was defined as using a hospital where phlebotomy and
specimen processing were performed at the same laboratory, which
did not include testing performed at satellite laboratories. Off-site
processing was defined as using a clinic, community hospital or private
facility where the phlebotomy and specimen processing were not per-
formed at the same location. For onsite processing, plasma for the
VWF assays was either analyzed onsite immediately after processing,
or frozen and later analyzed onsite or analyzed at a different location.
A comparison was not made between evaluating processing and ana-
lyzing of VWF assays onsite to processing onsite and sending frozen
samples off-site for analysis. Analyzing procedures were not collected
for assays performed after off-site processing.
Low VWF was defined as a VWF:RCo or VWF:Ag of 30IU/dL-
50IU/dL (or 30IU/dL-60IU/dL depending laboratory reference range)
while type 1 VWD was defined as VWF:Ag or VWF:RCo <30IU/dL on
at least one occasion. Prolongation of the prothrombin time (PT), acti-
vated partial thromboplastin time (aPTT) and specific factor deficien-
cies were determined based on individual laboratory reference ranges.
The only coagulation factor activities routinely collected were FVIII
and VWF. Hypofibrinogenemia was defined as a fibrinogen activity
less than 150 mg/dL. The consulting hematologist at each institution
defined pertinent bleeding symptoms (such as HMB) and determined
the final diagnosis as documented in the medical record.
2.5 | Data characteristics
Standardized case report forms through Research Electronic Data
Capture (REDCap), a free, secure, web based, HIPPA compliant appli-
cation were used to collect subject data. Information collected prior
to hematology consultation included: subject age, specialty of refer-
ring physician, referral reason, results of VWF assays (VWF:Ag, VWF:
RCo, FVIII activity and/or VWF multimer distribution), type of off-site
laboratory that performed VWF assays, distance from phlebotomy
site to processing site that performed VWF assays and value for other
hematologic and coagulation testing performed (Hgb, platelet count,
PT, aPTT and fibrinogen). Data collected at the hematology consulta-
tion included: subject age, bleeding symptoms, estrogen use, results
of VWF assays, institutional procedure for VWF assay processing and
analysis, value for other hematologic and coagulation testing per-
formed identical to above, including platelet function assay (PFA-100)
and platelet aggregometry (whole blood impedance and light transmis-
sion aggregometry) results. Final diagnosis was collected and deter-
mined by the consulting hematologist after clinical and laboratory
evaluation.
2.6 | Statistical methods
The primary objective of the statistical analysis was to estimate the
proportion of subjects with low VWF assays based on off-site
processing laboratory values and were confirmed (ie, concordant)
when these laboratory assays were repeated at the consulting hospital
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with onsite phlebotomy and processing. Either VWD or low VWF
diagnosis was classified first based only on the off-site values, and
then based only on the onsite values, and concordance between these
classifications was calculated. Basic summary statistics on patient age
and data collected prior to and at consultation were provided.
McNemarʼs test was utilized on paired test results to examine the
proportions of patients with low-test or high-test results pertaining to
VWF status, hematology or coagulation function. The exact P-value
from the McNemarʼs test was provided whenever frequency counts
fell at or below five. A two-sided P-value <.05 was deemed significant.
All computations were completed using the statistical software Stata
version 11.19 Missing data results for VWF assays were excluded and
analysis was performed only on subjects with paired VWD assay
results. Loss to follow up was relevant for final diagnosis only and
reported as unknown.
3 | RESULTS
3.1 | Characteristics of subjects
The 17 institutions identified 278 subjects between July 2013 and
October 2017. Fifteen subjects were under 12 years of age at the
time of diagnostic testing and excluded from the analysis. The main
analytic cohort included a total of 263 females. The median subject
age when VWF assays were drawn by the referring physician visit
was 15 years (range 12-50), and the majority of subjects, 72% (189),
had HMB as their referring complaint (Table 1). Primary care physi-
cians were most often the referring physician (63%, n = 167) followed
by obstetricians/gynecologists (24%, n = 64).
The median age at the hematology consultation was 15 years
(range 12-50) and 83% (217) reported HMB, followed by easy bruising
37% (96) and epistaxis 30% (80) stated in their initial hematology con-
sult note. Testing was conducted while on hormonal contraception in
99 (38%) subjects at the initial hematology consultation.
3.2 | Von Willebrand factor testing
A total of 251 (95IU/dL) subjects had both off-site and onsite sam-
ple processing assays for VWF:Ag, 223 (84IU/dL) subjects for
VWF:RCo, and 229 (87IU/dL) subjects for FVIII. Of the 251 sub-
jects who had VWF:Ag testing, 96 (38IU/dL) had low VWF:Ag with
off-site processing, but only 56 (22IU/dL) had low VWF:Ag with
onsite processing (Figure 1). Among 223 subjects with VWF:RCo
results, 122 (55IU/dL) had low VWF:RCo with off-site processing,
while only 71 (32IU/dL) were confirmed with onsite processing.
Similarly, among 229 subjects with paired FVIII assay results, 67
(29IU/dL) were low with off-site processing and less than half, 29
(13IU/dL), were confirmed with onsite processing. Higher propor-
tions of subjects demonstrated low VWF:Ag, VWF:RCo, and/or
FVIII with off-site processing compared to onsite (McNemarʼs test
P-value <.0005, for all assays) (Figure 1). Eighty-six (33IU/dL)
subjects had normal or elevated VWF:Ag and/or VWF:RCo prior to
their hematology consultation.
TABLE 1 Subject and referring physician characteristics
Total N = 263
Prior to consultation
Variable
Median age (range), y 15 (12–50)
Bleeding history/referral reason, n (%)a
Heavy menstrual bleeding 196 (75)
Epistaxis 35 (13)
Easy bruising 35 (13)
Gum bleeding 10 (4)
Post-partum bleeding 3 (1)
Post-surgical bleeding 9 (3)
Other gastrointestinal bleeding 0
Prolonged bleeding with lacerations -
Trauma -
Family history of VWD 27 (10)
Unspecified/other bleeding 3 (1)
Unknown 1 (0)
Type of referring physician, n (%)a
General practioner 168 (64)
Obstetrics/gynecology 64 (24)
Private hematologist/oncologist 10 (4)
Surgeon 4 (1.5)
Adolescent medicine 2 (1)
Other specialist 4 (1.5)
Unknown 10 (4)
Abbreviation: VWD, von Willebrand disease.
aSome subjects had >1 bleeding symptom or referral reason.
F IGURE 1 Graphical representation comparing von Willebrand
factor antigen, ristocetin co-factor and Factor VIII activity results in
patients who had both off-site and onsite testing. *Represents
statistically significant discordance between off-site vs onsite testing
[Color figure can be viewed at wileyonlinelibrary.com]
JAFFRAY ET AL. 1025
All three VWF assays (VWF:Ag, VWF:RCo and FVIII) were sent
in 210 (80IU/dL) subjects by referring physicians. Referring physi-
cians sent two assays, VWF:Ag and VWF:RCo in 8 (3IU/dL) sub-
jects, and only one assay (either VWF:Ag or VWF:RCo) in 44
(17IU/dL) subjects. At the onsite consulting institutions, VWF
assays were collected, processed and frozen for future analysis in
68IU/dL-73IU/dL of subjects depending on the assay. Assays were
analyzed immediately after processing in 10IU/dL-18IU/dL of sub-
jects at the onsite institutions. Consulting hematologists repeated
VWF testing more than once for 74 (28IU/dL) subjects. Subjects
with subnormal VWF assays at onsite institutions were routinely
re-tested again onsite.
Among the 56 subjects with low VWF:Ag onsite, 31 had
repeat testing onsite and 23 (74IU/dL) continued to be low.
Twenty-nine of the 71 subjects had repeat VWF:RCo onsite after
being initially low onsite and 24 (83IU/dL) continued to be low; 11
of the 29 subjects with initial low FVIII onsite had repeat testing
and eight subjects (73IU/dL) continued to have low levels onsite.
In comparison, among subjects with low VWF:Ag with off-site
processing, 58IU/dL (56/96) were low when repeated onsite.
Among the subjects with low VWF:RCo after off-site processing,
58IU/dL (71/122) were low when repeated onsite, and among sub-
jects with low FVIII with off-site processing, 43IU/dL (29/67) were
low when repeated on-site.
3.3 | Other hematologic testing
There were 89 subjects (34%) who had a PT performed with both
off-site and onsite processing, with 15 subjects initially having a
prolonged PT and 10 (66%) normalized when retested with onsite
processing (P = .09) (Table 2). Only 117 subjects (44%) had an
aPTT performed with off-site processing and then repeated onsite
processing. A prolonged aPTT was noted in 26 subjects with off-
site processing, and 17 (65%) normalized when retested with
onsite processing during the hematology consultation (P = .041). A
fibrinogen level was evaluated in 26 subjects by the referring
physician and in 158 subjects by the consulting physician. Hypo-
fibrinogenemia was identified in only one subject by the consult-
ing hematologist, and final diagnosis was not made due to lack of
follow up.
Note, PFA-100 was performed in 121 subjects by the consulting
hematologist, and 73 (60%) subjects had a normal result. Of the 48
subjects with abnormal results, 13 subjects had isolated prolongation
of the collagen/epinephrine cartridge, 12 subjects had isolated prolon-
gation of the collagen/adenosine diphosphate (ADP) cartridge and 23
subjects had prolongation of both closure times. The majority of sub-
jects (n = 33, 69%) with abnormal PFA-100 results were given the
diagnosis of VWD or low VWF. Other identified bleeding disorders in
subjects with abnormal PFA-100 results included immune thrombocy-
topenia purpura, platelet dysfunction and factor deficiency.
Platelet aggregation testing was performed in 60 (23%) subjects
at the consulting institution and 10 subjects had an abnormality with
at least one agonist. The majority of abnormalities were with epineph-
rine or ADP secretion. One subject was given the diagnosis of VWD
and had decreased aggregation to both ristocetin and epinephrine.
Other identified bleeding disorders consisted of platelet dysfunction,
immune thrombocytopenia purpura and factor deficiency.
3.4 | Final diagnosis
Less than 40% (100) of the subjects were ultimately diagnosed with
VWD by the consulting hematologist. Of the 100 subjects, 94 (36%)
were diagnosed with type 1 VWD, five (2%) with type 2 and one sub-
ject was diagnosed with type 3 VWD. Less than 20% (47) of the sub-
jects were diagnosed with an alternative bleeding disorder such as
low VWF (7%, n = 19), factor deficiency (2%, n = 6), platelet dysfunc-
tion (2%, n = 5), and other unclassified bleeding disorder (6%, n = 17).
However, approximately 40% of the subjects referred to a hematolo-
gist for the concern of a bleeding disorder had a normal hemostatic
evaluation (Figure 2).
4 | DISCUSSION
Increased awareness that HMB may be the only bleeding symptom in
young women has led to primary care physicians and obstetricians/
gynecologists to conduct initial hemostatic evaluation for VWD.8,9
Primarily regulated by hospital and insurance contracts, these physi-
cians typically send the VWF assays to coagulation laboratories with
offsite processing that are generally more cost efficient due to the
TABLE 2 Comparing off-site to onsite testing of other hematologic laboratory assays
Total N = 263
Laboratory test Total off-site processing n (%) Abnormal off-site n (%) Total onsite processing n (%) Normalized onsite n (%) P-value
PT 156 (59) 22 (14) 152 (58) 10 (45) P = .09
aPTT 171 (65) 30 (18) 172 (65) 17 (57) P = .04
Fibrinogen 26 (10) 0 158 (60) a a
PFA-100 0 0 121 (46) 73 a
Abbreviations: aPTT, activated partial thromboplastin time PFA, platelet function assay; PT, prothrombin thrombin time.
aRefers to non-applicable or statistical testing was not conducted.
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high volumes of testing, compared to hospital-based laboratories with
onsite processing. In many cases these companies with off-site
processing have multiple locations for phlebotomy that can be more
convenient for patients, compared to academic-based coagulation lab-
oratories that may require patients to travel far distances. In this large,
multi-institutional study, significant differences were seen between
assays drawn and processed off-site where phlebotomy and
processing are conducted in separate locations, compared to samples
drawn and processed in one location (onsite). Abnormal VWF:Ag,
VWF:RCo, and/or FVIII results identified with off-site testing normal-
ized in 40-60% of the subjects when retested with onsite processing
under the guidance of a consulting hematologist.
We do acknowledge the possibility of VWF variation within an
individual. Subjects who initially had low VWF assay results at labora-
tories with off-site processing may have had a stress induced
response when tested at laboratories with onsite processing, causing
a normalization of the results or they may have a rapid clearance of
their VWF such as in type 1C VWD.20 This may also reflect the inher-
ent variability of VWD where 16 different patterns of VWF:RCo,
VWF:Ag, FVIII and bleeding time have been reported in a well
described cohort of 50 individuals in 25 families.21 However, it
appears the main discordance between assay results found in our
study is most likely secondary to delayed or inappropriate processing
of the specimen prior to analyzing. Concerns have been raised that
mislabeling of VWD is increasing due to these pre-analytical variables,
such as delay in centrifuging the sample,heat inactivation or cold acti-
vation of the sample, that are outside of the scope of the analyzing
laboratory.22 Due to the concern for misdiagnosis, many patients
inevitably require VWF testing to be performed multiple times to
establish a diagnosis or confirm normal VWF assay results, especially
when they were previously low with off-site processing.17 Our study
found one-quarter of the subjects had VWF assays repeated up to
three times at the consulting institution in order to confirm the final
laboratory diagnosis of VWD. Depending on the assay, 6%-21% of
subjects who initially had normal results with off-site processing had
low levels with onsite processing, which may be due to stress induced
elevation at the first blood draw with the referring physician. These
variations underscore the need for repeat testing in patients with nor-
mal testing results and significant bleeding or to confirm VWD in
patients with low VWF assay results.
Our results are consistent with a previous, smaller, single institu-
tion study, which found normalization of VWF assays in 73-100% of
subjects when the off-site testing was repeated at their onsite facil-
ity.23 Our large, multi-institutional study provides additional verifica-
tion that the use of laboratories with off-site processing with
potential multiple pre-analytical variables affects VWF assays, causing
falsely low levels and misdiagnosis of VWD.
Although primary care physicians and non-hematology specialists
are ordering VWF testing, our study found referring physicians sent a
partial work-up for VWD in 20% of subjects. Thus, although referring
physicians are considering the diagnosis of VWD and bleeding disor-
ders in females with HMB, attention to improved education regarding
the required laboratory investigations for VWD testing is necessary.
In addition, due to the challenges of interpreting VWF assays as well
as the inherent variability of VWF levels, consultation with hematolo-
gists for final VWD diagnosis is imperative. Although laboratory assay
results are crucial a detailed personal history of bleeding and family
history of bleeding or VWD are important components of this diagno-
sis. as Also important are newer assays such as collagen binding and
GPIbM assays, which are now becoming standard to assist with esta-
blishing an accurate diagnosis. For patients with negative or inconclu-
sive VWF testing, additional evaluation by a hematologist is also
necessary, to evaluate for other bleeding disorders when the clinical
context warrants.
Differences were not as dramatic between PT and aPTT assays
when tested with off-site and onsite processing as expected. Since it
was not a requirement of the study to have a PT and aPTT obtained
by the referring or consulting physician, this was only performed in
60-65% of the subjects. The decreased sample size may have added
to a lack of significance seen between these assay results.
F IGURE 2 Final diagnosis of subjects by the consulting hematologist after clinical and laboratory evaluation [Color figure can be viewed at
wileyonlinelibrary.com]
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Overall, less than half of the subjects were ultimately diagnosed
with VWD or low VWF, and 39% had a normal hemostatic evaluation.
Many patients with significant bleeding and normal coagulation testing
are given the diagnosis of bleeding of unknown cause (BUC). Prevalence
of BUC may be as high as 40% in patients undergoing investigation for
a bleeding disorder.24 These patients still suffer from typical mucocuta-
neous bleeding, such as HMB, post-surgical bleeding and bleeding after
dental extractions.25 With almost 40% of our subjects with significant
bleeding, but a normal hemostatic work-up, improved specialized coag-
ulation testing and further investigation of bleeding causes in this
patient group are needed. Hopefully, next generation gene sequencing
will uncover underlying disorders of hemostasis in such patients.26
This study does have several limitations besides its retrospective
design. The first is the inability to determine the specific duration of
time or transit details between sample collections to off-site
processing. The actual duration may have been minutes or hours and
the transportation of the blood samples may have been in a tempera-
ture cooler or stored only in collection bags. Details regarding hospital
policies for VWF assay collection, processing and analyzing were col-
lected for consulting institutions with onsite processing, but were not
available for laboratories with off-site processing. A second limitation
is that not all potential subjects were included in the study due to
missing laboratory information (typically from the referring physi-
cians). Data from missing subjects would not have affected the main
results of the study but may have provided a larger sample size to
identify statistical differences. A third limitation arises from the VWF
assays; the wide coefficient of variation of the VWF assays and VWF
assays in the 20% range and the fact that the assays were not done
with identical instrumentation and reagents.27 To address these limi-
tations, a study could be designed to simultaneously draw two sam-
ples: one to be processed onsite and one to processed off-site with
both locations following a specific protocol.
In conclusion, HMB is increasingly recognized as a symptom of an
underlying bleeding disorder, leading to increased evaluation, diagno-
sis, and treatment of bleeding disorders in women. Significant differ-
ences were seen between assays drawn and processed off-site where
phlebotomy and processing are in separate locations, compared to
samples drawn, prepared and processed in one location. These results
highlight the need for VWF testing to ideally be both drawn and
processed with little delay at laboratories with onsite processing
under the guidance of a hematologist.
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